{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T04:37:27Z","timestamp":1789706247813,"version":"4.0.1"},"reference-count":37,"publisher":"Public Library of Science (PLoS)","issue":"12","license":[{"start":{"date-parts":[[2014,12,3]],"date-time":"2014-12-03T00:00:00Z","timestamp":1417564800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0114483","type":"journal-article","created":{"date-parts":[[2014,12,3]],"date-time":"2014-12-03T19:10:06Z","timestamp":1417633806000},"page":"e114483","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":44,"title":["Combination of MiR-103a-3p and Mesothelin Improves the Biomarker Performance of Malignant Mesothelioma Diagnosis"],"prefix":"10.1371","volume":"9","author":[{"given":"Daniel G.","family":"Weber","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Swaantje","family":"Casjens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Georg","family":"Johnen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oleksandr","family":"Bryk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irina","family":"Raiko","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beate","family":"Pesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jens","family":"Kollmeier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Torsten T.","family":"Bauer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Br\u00fcning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2014,12,3]]},"reference":[{"key":"ref1","first-page":"491","article-title":"Malignant pleural mesothelioma: an epidemiological perspective","volume":"1","author":"BM Robinson","year":"2012","journal-title":"Ann Cardiothorac Surg"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/aje\/kwh025","article-title":"Mesothelioma trends in the United States: an update based on Surveillance, Epidemiology, and End Results Program data for 1973 through 2003","volume":"159","author":"B Price","year":"2004","journal-title":"Am J Epidemiol"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/sj.bjc.6602307","article-title":"The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050","volume":"92","author":"JT Hodgson","year":"2005","journal-title":"Br J Cancer"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.2486\/indhealth.MS1184","article-title":"Future trends of mesothelioma mortality in Japan based on a risk function","volume":"50","author":"T Myojin","year":"2012","journal-title":"Ind Health"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2636","DOI":"10.1200\/JCO.2003.11.136","article-title":"Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma","volume":"21","author":"NJ Vogelzang","year":"2003","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"Yoneda K, Tanaka F, Kondo N, Hashimoto M, Takuwa T, <etal>et al<\/etal>.<bold>.<\/bold> (2013) Circulating Tumor Cells (CTCs) in Malignant Pleural Mesothelioma (MPM). Ann Surg Oncol. In press.","DOI":"10.1245\/s10434-013-3399-2"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Jakubec P, Pelclova D, Smolkova P, Kolek V, Nakladalova M (2014) Significance of serum mesothelin in an asbestos-exposed population in the Czech Republic. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub. In press.","DOI":"10.5507\/bp.2014.015"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.bbapap.2013.12.007","article-title":"Biomarker research with prospective study designs for the early detection of cancer","volume":"1844","author":"B Pesch","year":"2014","journal-title":"Biochim Biophys Acta"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1373\/clinchem.2006.079327","article-title":"MESOMARK: a potential test for malignant pleural mesothelioma","volume":"53","author":"HL Beyer","year":"2007","journal-title":"Clinical Chemistry"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1186\/1471-2407-10-242","article-title":"Development of an enzyme-linked immunosorbent assay for the detection of human calretinin in plasma and serum of mesothelioma patients","volume":"10","author":"I Raiko","year":"2010","journal-title":"BMC Cancer"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1056\/NEJMoa1115050","article-title":"Fibulin-3 as a blood and effusion biomarker for pleural mesothelioma","volume":"367","author":"HI Pass","year":"2012","journal-title":"The New England journal of medicine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"e18232","DOI":"10.1371\/journal.pone.0018232","article-title":"Association of MiR-126 with Soluble Mesothelin-Related Peptides, a Marker for Malignant Mesothelioma","volume":"6","author":"L Santarelli","year":"2011","journal-title":"PLoS One"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1184","DOI":"10.1097\/JTO.0b013e3182572e83","article-title":"Increased circulating miR-625-3p: a potential biomarker for patients with malignant pleural mesothelioma","volume":"7","author":"MB Kirschner","year":"2012","journal-title":"J Thorac Oncol"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"e30221","DOI":"10.1371\/journal.pone.0030221","article-title":"Identification of miRNA-103 in the Cellular Fraction of Human Peripheral Blood as a Potential Biomarker for Malignant Mesothelioma - A Pilot Study","volume":"7","author":"DG Weber","year":"2012","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"e004145","DOI":"10.1136\/bmjopen-2013-004145","article-title":"Diagnostic values of soluble mesothelin-related peptides for malignant pleural mesothelioma: updated meta-analysis","volume":"4","author":"A Cui","year":"2014","journal-title":"BMJ Open"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3233\/CBM-2007-3602","article-title":"Soluble mesothelin-related peptides (SMRP) - High stability of a potential tumor marker for mesothelioma","volume":"3","author":"DG Weber","year":"2007","journal-title":"Cancer biomarkers: section A of Disease markers"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e179","DOI":"10.1093\/nar\/gni178","article-title":"Real-time quantification of microRNAs by stem-loop RT-PCR","volume":"33","author":"C Chen","year":"2005","journal-title":"Nucleic Acids Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"95","DOI":"10.4137\/BMI.S5522","article-title":"Assessment of mRNA and microRNA Stabilization in Peripheral Human Blood for Multicenter Studies and Biobanks","volume":"5","author":"DG Weber","year":"2010","journal-title":"Biomark Insights"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1378\/chest.07-0013","article-title":"Combined CA125 and Mesothelin Levels for the Diagnosis of Malignant Mesothelioma","volume":"132","author":"J Creaney","year":"2007","journal-title":"Chest"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1007\/s00204-010-0580-2","article-title":"Performance of biomarkers SMRP, CA125, and CYFRA 21-1 as potential tumor markers for malignant mesothelioma and lung cancer in a cohort of workers formerly exposed to asbestos","volume":"85","author":"M Gube","year":"2011","journal-title":"Arch Toxicol"},{"key":"ref21","first-page":"5517","article-title":"YKL-40 and Mesothelin in the Blood of Patients with Malignant Mesothelioma, Lung Cancer and Asbestosis","volume":"33","author":"M Corradi","year":"2013","journal-title":"Anticancer Res"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1097\/JTO.0b013e31821e1c08","article-title":"Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma","volume":"6","author":"A Cristaudo","year":"2011","journal-title":"J Thorac Oncol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1097\/JTO.0b013e31828f696b","article-title":"Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer","volume":"8","author":"T Muley","year":"2013","journal-title":"J Thorac Oncol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"276","DOI":"10.2174\/1871520611313020014","article-title":"The role of mesothelin in tumor progression and targeted therapy","volume":"13","author":"Z Tang","year":"2013","journal-title":"Anticancer Agents Med Chem"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1261\/rna.045757.114","article-title":"MiR-103a-3p targets the 5\u2032 UTR of GPRC5A in pancreatic cells","volume":"20","author":"H Zhou","year":"2014","journal-title":"RNA"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"963","DOI":"10.4161\/cbt.8.10.8417","article-title":"GPRC5A: A potential tumor suppressor and oncogene","volume":"8","author":"T Acquafreda","year":"2009","journal-title":"Cancer Biol Ther"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.humpath.2014.03.006","article-title":"Diagnostic utility of immunohistochemistry in distinguishing between epithelioid pleural mesotheliomas and breast carcinomas: a comparative study","volume":"45","author":"NG Ordonez","year":"2014","journal-title":"Hum Pathol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"e100664","DOI":"10.1371\/journal.pone.0100664","article-title":"A prognostic model of triple-negative breast cancer based on miR-27b-3p and node status","volume":"9","author":"S Shen","year":"2014","journal-title":"PLoS One"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.3892\/or.2013.2263","article-title":"Expression profiles of microRNAs and their target genes in papillary thyroid carcinoma","volume":"29","author":"X Liu","year":"2013","journal-title":"Oncology reports"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"e7689","DOI":"10.1371\/journal.pone.0007689","article-title":"Expression profile of MicroRNAs in young stroke patients","volume":"4","author":"KS Tan","year":"2009","journal-title":"PLoS One"},{"key":"ref31","first-page":"31","article-title":"Clinical utility of diagnostic markers for malignant pleural mesothelioma","volume":"71","author":"BD Grigoriu","year":"2009","journal-title":"Monaldi Arch Chest Dis"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1136\/jclinpath-2013-201609","article-title":"Challenges and controversies in the diagnosis of malignant mesothelioma: Part 2. Malignant mesothelioma subtypes, pleural synovial sarcoma, molecular and prognostic aspects of mesothelioma, BAP1, aquaporin-1 and microRNA","volume":"66","author":"DW Henderson","year":"2013","journal-title":"J Clin Pathol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1515\/CCLM.2004.128","article-title":"Inherent biological variation and reference values","volume":"42","author":"CG Fraser","year":"2004","journal-title":"Clin Chem Lab Med"},{"key":"ref34","first-page":"94","article-title":"The Impact of Hemolysis on Cell-Free microRNA Biomarkers","volume":"4","author":"MB Kirschner","year":"2013","journal-title":"Front Genet"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1158\/1055-9965.EPI-08-0150","article-title":"Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer","volume":"17","author":"KA Lowe","year":"2008","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1515\/CCLM.2007.112","article-title":"Mesothelin family proteins and diagnosis of mesothelioma: analytical evaluation of an automated immunoassay and preliminary clinical results","volume":"45","author":"F Di Serio","year":"2007","journal-title":"Clin Chem Lab Med"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1373\/clinchem.2012.185009","article-title":"MicroRNA analysis: is it ready for prime time?","volume":"59","author":"GJ Tsongalis","year":"2013","journal-title":"Clinical Chemistry"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0114483","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,18]],"date-time":"2019-08-18T03:41:19Z","timestamp":1566099679000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0114483"}},"subtitle":[],"editor":[{"given":"Deborah A.","family":"Altomare","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2014,12,3]]},"references-count":37,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2014,12,3]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0114483","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,12,3]]}}}